Donald A. Kalkofen, Chief Financial Officer of Genvor Inc, filed a Form 4 on November 20, 2026, disclosing the acquisition of a nonqualified stock option to purchase 575,000 shares of common stock, granted on November 19, 2026, under the company's 2026 Omnibus Equity Incentive Plan.

Key Highlights

  • Reporting person and role: Donald A. Kalkofen, Chief Financial Officer of Genvor Inc (OTC:GNVR).
  • Transaction: Acquisition (Code A) of a nonqualified stock option to purchase 575,000 shares of common stock on November 19, 2026.
  • Exercise price: $0.2664 per share, equal to the fair market value on November 18, 2026, as the average of closing bid and asked prices on the OTCQB market.
  • Expiration date: November 19, 2036.
  • Vesting: 425,000 shares vest in twelve equal monthly installments on each monthly anniversary of May 18, 2026; 150,000 shares vest in full upon an Uplisting Event as defined in the Amended and Restated Acting Chief Financial Officer Services Agreement dated May 21, 2026.
  • Price of derivative security: $0 (no cost to acquire the option).
  • Beneficial ownership following transaction: 575,000 derivative securities, held directly.

Genvor CFO Kalkofen Granted 575,000-Share Option Under 2026 Equity Plan

According to the Form 4 filed with the SEC on November 20, 2026, Donald A. Kalkofen, serving as Chief Financial Officer of Genvor Inc (OTC:GNVR), reported the acquisition of a nonqualified stock option on November 19, 2026. The option carries an exercise price of $0.2664 per share, which the filing states equals the fair market value of a share of common stock on the date of grant, determined as "the average of the closing bid and asked prices on the OTCQB market for the last preceding date on which there was a sale, which was November 18, 2026."

The filing discloses that the grant was made under the issuer's 2026 Omnibus Equity Incentive Plan pursuant to Kalkofen's Amended and Restated Acting Chief Financial Officer Services Agreement dated May 21, 2026. Of the 575,000 shares underlying the option, 425,000 vest in twelve equal monthly installments on each monthly anniversary of May 18, 2026, with installments whose vesting dates preceded the grant date vested on the grant date. The remaining 150,000 shares vest in full upon an Uplisting Event as defined in that agreement.

The filing further notes that the option "may not be exercised until a registration statement on Form S-8 covering the underlying shares has become effective." Share amounts are stated before any reverse stock split, and both the number of shares and the exercise price are subject to proportionate adjustment for any reverse stock split or other change in capitalization. The grant was approved by Genvor's Board of Directors and the filing states it "is exempt under Rule 16b-3(d)." Following the reported transaction, Kalkofen beneficially owns 575,000 derivative securities, held directly.

What Was Disclosed

Genvor Inc CFO Donald A. Kalkofen reported the acquisition of a nonqualified stock option covering 575,000 shares at an exercise price of $0.2664, granted November 19, 2026, expiring November 19, 2036, under the company's 2026 Omnibus Equity Incentive Plan.